Aortic Aneurysm, Abdominal
Conditions
Keywords
Endovascular, EVAR, Neck Angulation
Brief summary
The First In Human (FIH) study is a long-term, single center, non-randomized study established by Lombard Medical, Inc. to collect on-label data in the clinical setting on patients undergoing endovascular repair with IntelliFlex™, the latest generation of the Aorfix™ AAA Flexible Stent Graft Delivery System, for treatment of abdominal aortic and aorto-iliac aneurysms in anatomy where the aorta in the aneurysm neck is bent through an angle between 0° and 90°.
Interventions
DEVICEEndovascular aneurysm repair EVAR
Sponsors
Lombard Medical
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Diagnosed abdominal aortic aneurysm with indication for endovascular repair. 2. Intention to electively implant the Aorfix™ Stent Graft System with IntelliFlex™ Delivery Device.
Exclusion criteria
1. Do not comply with the indications for Aorfix™ in the IFU. 2. Unwillingness or inability to comply with the recommended follow-up assessments according to the standards of care of the investigative site. 3. Unwillingness or inability to provide informed consent to both the study and the EVAR procedure. 4. Patients in whom Aorfix™ is being placed as a secondary procedure to a previous surgical or endovascular treatment of an AAA other than with another Aorfix™ graft.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with Successful Implant Delivery (30d) | 1 Month | Successful implant delivery is also called Primary Technical Success, defined as successful introduction and deployment of the device in the absence of surgical conversion or mortality, Type I or III endoleaks, or graft limb obstruction. The numbers of participants having Primary Technical Success on completion of the index procedure and Clinical Success 12 months after the procedure will be recorded. |
| Number of participants with Treatment Success (1year) | 12 Months | Treatment success, or Clinical Success, requires successful deployment of the endovascular device at the intended location without death as a result of aneurysm-related treatment, Type I or III endoleak, graft infection or thrombosis, aneurysm expansion (diameter \>=5 mm, or volume \>=5%), aneurysm rupture, or conversion to open repair. The numbers of participants having Primary Technical Success on completion of the index procedure and Clinical Success 12 months after the procedure will be recorded. |
Outcome results
None listed